Lateral flow assay developed by RAPIvD published in Toxicology Letters

Pharmista, already a participant in the SmiLe life sciences start-up business incubator program has now been accepted to the BioInnovation Institute (BII) Venture Lab program in Copenhagen.

Pharmista Technologies, has announced that the European Patent Organisation (EPO) has approved their European patent application for "A REUSABLE TEST DEVICE"

RAPIvD has assisted with the invention of a reusable pregnancy device for Swedish company, Pharmista Technologies

RAPIvD has signed a partnership agreement with Stream Bio to use their conjugated polymer nanoparticles (CPNs) in lateral flow assay development projects.

RAPIvD has announced successful prototype tests in developing a rapid multiplexed influenza A/B lateral flow assay.

RAPIvD has achieved certification for
meeting ISO 13485 medical devices standards for ‘contract development and manufacture of lateral
flow assays for IVD’

RAPIvD has announced the sale of a 19% stake in the business to the publicly listed Vancouver-based, Gemina Labs.